A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?

Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelm...

Descripción completa

Detalles Bibliográficos
Autores principales: Davoodi-Moghaddam, Zeinab, Jafari-Raddani, Farideh, Noori, Maryam, Bashash, Davood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941575/
https://www.ncbi.nlm.nih.gov/pubmed/36773442
http://dx.doi.org/10.1016/j.tranon.2023.101636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941575/
https://www.ncbi.nlm.nih.gov/pubmed/36773442
http://dx.doi.org/10.1016/j.tranon.2023.101636

Ejemplares similares